MYC and small cell lung carcinoma: These markers - particularly TTF1 - could be easily translated into clinical practice and present novel candidate predictive markers that could be immediately leveraged for chemo-refractory SCLC patients to select treatment with rovalpituzumab tesirine (TTF1-positive) versus other targeted agents such as alisertib (TTF1-negative, cMYC-high).